und es weihnachtet sehr! - 500 Beiträge pro Seite

[Cyberhexe]

Die FDA hat Natalizumab zugelassen. Um Verwechslungen mit anderen Medikamenten auszuschliessen hat sie jedoch auf eine Namensänderung bestanden, so dass Natalizumab nicht unter dem bisher verwendeten TradeMark Antegren sondern unter dem etwas gewöhnungsbedürftigen Namen TYSABRI zugelassen ist. Egal, an den vielversprechenden Prognosen wird sich deswegen nichts ändern. Bin mal gespannt wie die Börse bis Ende November darauf reagiert. Alles unter 35$ wäre eine Enttäuschung.


http://biz.yahoo.com/bw/041123/235792_1.html

Biogen Idec (NASDAQ: BIIB - News) and Elan Corporation, plc (NYSE: ELN - News) announced today that the U.S. Food and Drug Administration (FDA) has approved TYSABRI® (natalizumab), formerly referred to as ANTEGREN®, as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

[Cyberhexe]

Im Anschluss an die Zulassung hat S&P das Kreditrating für Elan erhöht:

DOW JONES NEWSWIRES
November 23, 2004 4:47 p.m.

The following is a press release from Standard & Poor`s:
NEW YORK (Standard & Poor`s) Nov. 23, 2004--Standard & Poor`s Ratings Services said today that it raised the corporate credit and senior unsecured debt ratings on specialty pharmaceutical maker Elan Corp. to `B` from `B-`. The rating action reflects the Dublin, Ireland-based company`s increased liquidity and anticipates the upcoming market launch of its very promising multiple sclerosis treatment Antegren, a drug that could generate annual sales well in excess of $1 billion.

At the same time, Standard & Poor`s raised its ratings on subsidiary Elan Finance plc`s recently completed offering of $1.15 billion in senior unsecured notes to `B` from `B-`. These consist of $850 million in 7.75% fixed-rate notes due 2011 and $300 million in floating rate notes due 2011. In addition, Standard & Poor`s raised the ratings on Elan Pharmaceutical Investments III Ltd.`s (EPIL III) $390 million in subordinated notes to `B` from `CCC`. The senior unsecured debt rating on Elan Corp.`s $460 million in convertible notes was raised to `CCC+` from `CCC`. (These are subordinate to the EPIL III notes.)

All the ratings have been removed from CreditWatch, where they were placed Nov. 1, 2004, after the company announced it would issue senior unsecured notes to refinance a significant portion of the EPIL III notes and increase liquidity ahead of the planned Antegren launch. The recently completed debt offering and subsequent retirement of $351 million of EPIL III`s notes adds roughly $800 million to the coffers of Elan Corp.

The outlook is positive.

...